Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Pilka, ES"'
Autor:
Tsoumpra, MK, Muniz, JR, Barnett, BL, Kwaasi, AA, Pilka, ES, Kavanagh, KL, Evdokimov, A, Walter, RL, Von Delft, F, Ebetino, FH, Oppermann, U, Russell, RG, Dunford, JE
Publikováno v:
Bone. 81:478-486
Farnesyl pyrophosphate synthase (FPPS) is the major molecular target of nitrogen-containing bisphosphonates (N-BPs), used clinically as bone resorption inhibitors. We investigated the role of threonine 201 (Thr201) and tyrosine 204 (Tyr204) residues
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Guirguis AA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia., Ofir-Rosenfeld Y; Storm Therapeutics Ltd, Cambridge, United Kingdom., Knezevic K; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Blackaby W; Storm Therapeutics Ltd, Cambridge, United Kingdom., Hardick D; Storm Therapeutics Ltd, Cambridge, United Kingdom., Chan YC; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Motazedian A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Gillespie A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Vassiliadis D; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Lam EYN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Tran K; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Andrews B; Storm Therapeutics Ltd, Cambridge, United Kingdom., Harbour ME; Storm Therapeutics Ltd, Cambridge, United Kingdom., Vasiliauskaite L; Storm Therapeutics Ltd, Cambridge, United Kingdom., Saunders CJ; Storm Therapeutics Ltd, Cambridge, United Kingdom., Tsagkogeorga G; Storm Therapeutics Ltd, Cambridge, United Kingdom.; Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom., Azevedo A; Storm Therapeutics Ltd, Cambridge, United Kingdom., Obacz J; Storm Therapeutics Ltd, Cambridge, United Kingdom., Pilka ES; Evotec (UK) Ltd, Abingdon, United Kingdom., Carkill M; Charles River Laboratories, Portishead, United -Kingdom., MacPherson L; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Wainwright EN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Liddicoat B; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Blyth BJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Albertella MR; Storm Therapeutics Ltd, Cambridge, United Kingdom., Rausch O; Storm Therapeutics Ltd, Cambridge, United Kingdom., Dawson MA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, -Victoria, Australia.
Publikováno v:
Cancer discovery [Cancer Discov] 2023 Oct 05; Vol. 13 (10), pp. 2228-2247.
Autor:
Kellici TF; Evotec (UK) Ltd, Abingdon, UK. Electronic address: tahsin.kellici@evotec.com., Pilka ES; Evotec (UK) Ltd, Abingdon, UK., Bodkin MJ; Evotec (UK) Ltd, Abingdon, UK.
Publikováno v:
Trends in pharmacological sciences [Trends Pharmacol Sci] 2021 Jun; Vol. 42 (6), pp. 431-433. Date of Electronic Publication: 2021 Mar 26.
Autor:
Yankova E; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Storm Therapeutics Ltd, Cambridge, UK., Blackaby W; Storm Therapeutics Ltd, Cambridge, UK., Albertella M; Storm Therapeutics Ltd, Cambridge, UK., Rak J; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., De Braekeleer E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., Tsagkogeorga G; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.; Storm Therapeutics Ltd, Cambridge, UK., Pilka ES; Evotec (UK) Ltd, Abingdon, UK., Aspris D; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; The Center for the Study of Hematological Malignancies/Karaiskakio Foundation, Nicosia, Cyprus., Leggate D; Storm Therapeutics Ltd, Cambridge, UK., Hendrick AG; Storm Therapeutics Ltd, Cambridge, UK., Webster NA; Storm Therapeutics Ltd, Cambridge, UK., Andrews B; Storm Therapeutics Ltd, Cambridge, UK., Fosbeary R; Storm Therapeutics Ltd, Cambridge, UK., Guest P; Storm Therapeutics Ltd, Cambridge, UK., Irigoyen N; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK., Eleftheriou M; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK., Gozdecka M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK., Dias JML; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Bannister AJ; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK., Vick B; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.; German Consortium for Translational Cancer Research (DKTK), Munich, Germany., Jeremias I; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.; German Consortium for Translational Cancer Research (DKTK), Munich, Germany.; Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University München, Munich, Germany., Vassiliou GS; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.; The Center for the Study of Hematological Malignancies/Karaiskakio Foundation, Nicosia, Cyprus., Rausch O; Storm Therapeutics Ltd, Cambridge, UK. oliver.rausch@stormtherapeutics.com., Tzelepis K; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK. kt404@cam.ac.uk.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk., Kouzarides T; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.
Publikováno v:
Nature [Nature] 2021 May; Vol. 593 (7860), pp. 597-601. Date of Electronic Publication: 2021 Apr 26.
Autor:
Kellici TF; Evotec (UK) Ltd, Abingdon, UK. Electronic address: tahsin.kellici@evotec.com., Pilka ES; Evotec (UK) Ltd, Abingdon, UK., Bodkin MJ; Evotec (UK) Ltd, Abingdon, UK.
Publikováno v:
Drug discovery today [Drug Discov Today] 2021 Feb; Vol. 26 (2), pp. 442-454. Date of Electronic Publication: 2020 Nov 28.
Autor:
Pilka ES; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, UK., James T; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, UK., Lisztwan JH; Evotec (UK) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, UK. Electronic address: joanna.lisztwan@evotec.com.
Publikováno v:
Drug discovery today [Drug Discov Today] 2015 Jun; Vol. 20 (6), pp. 743-9. Date of Electronic Publication: 2014 Dec 31.